Table 2.
Theoretical coverage of combination vaccines in the Auckland GAS isolates.
| Vaccine | Components | Total no. isolates (%) | Māori no. isolates (%) | Pacific Peoples no. isolates (%) | Other no. isolates (%) | Number variants (aa) |
|---|---|---|---|---|---|---|
| GSK-combo | SLO | 468 (99) | 155 (98.7) | 163 (100) | 149 (100) | 36 |
| SpyCEP | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 74 | |
| SpyAD | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 56 | |
| GAC (gacI) | 467 (99.5) | 156 (99.3) | 162 (99.3) | 149 (100) | 15 | |
| 1 antigen present | 469 (100) | 157 (100) | 163 (100) | 149 (100) | – | |
| Spy7 | Spy0651 | 468 (99.7) | 157 (100) | 162 (99.3) | 149 (100) | 61 |
| Spy0762 | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 7 | |
| Spy0942 | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 10 | |
| PulA | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 65 | |
| OppA | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 33 | |
| SpyAD | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 56 | |
| 1 antigen present | 469 (100) | 157 (100) | 163 (100) | 149 (100) | – | |
| Combo5 | TF | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 20 |
| ScpA | 453 (96.5) | 152 (96.8) | 153 (93.8) | 148 (99.3) | 82 | |
| SpyCEP | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 74 | |
| ADI | 469 (100) | 157 (100) | 163 (100) | 149 (100) | 11 | |
| SLO | 468 (99.7) | 155 (98.7) | 163 (100) | 149 (100) | 36 | |
| 1 antigen present | 469 (100) | 157 (100) | 163 (100) | 149 (100) | – | |
| J8 | J8.0 | 189 (40) | 69 (44) | 64 (39) | 56 (38) | 1 |
| J8.1 | 214 (46) | 67 (43) | 71 (44) | 76 (51) | 1 | |
| 1 peptide presenta | 403 (86) | 136 (87) | 135 (83) | 132 (82) | 2 | |
| Combivax | p∗17b | 189 (40) | 69 (44) | 64 (39) | 56 (38) | – |
| S2 | 276 (59) | 102 (65) | 83 (51) | 91 (61) | 2 | |
| 1 peptide present | 327 (70) | 119 (76) | 112 (69) | 96 (64) | – |
a
Assuming cross-reactivity between J8 and J8.1 as described.36
b
Allowing 2 mismatches to p∗17 sequence.